Chief Executive Officer, Idera Pharmaceuticals; Former President, Chief Executive Officer and Chairman, ViroPharma
Vin Milano is chief executive officer of Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases. Prior to Idera, Vin was president, chief executive officer and chairman of the board of directors of ViroPharma Incorporated (acquired by Shire Pharmaceuticals in January 2014), which focused on bringing innovative therapies to market for serious, unmet medical needs. ViroPharma’s lead product was Cinryze®, approved and commercially available in the United States, for the prevention of hereditary angioedema attacks and in Europe for both the treatment and prevention of hereditary angioedema attacks, a rare disease. Vin joined the company in 1996 and served as vice president, chief financial officer and treasurer from 1997 to 2006. He was instrumental in building the company, including leading efforts in raising nearly $900 million in capital, as well as the acquisitions of Lev Pharmaceuticals and the drug Vancocin from Eli Lilly. Vin played critical roles in all business development and investor relations activities for ViroPharma and contributed significantly to establishing the strategic focus of the company. Prior to joining ViroPharma, he served as senior manager at KPMG LLP, an independent registered public accounting firm. Vin received his B.S. in accounting from Rider College.